VIZZ (aceclidine hydrochloride)
VIZZ is a cholinergic agonist used to help adults who have presbyopia. This medication helps patients with age-related near vision loss by improving their visual focus. It is prescribed to enhance clarity by creating a specific physical change in the eye's pupil.
How VIZZ Works
This drug works by stimulating muscarinic receptors on the smooth muscles of the eye, specifically targeting the iris sphincter. When it binds, it causes the pupil to contract, creating a pinhole effect that extends the eye's depth of focus. This process improves vision with minimal impact on the ciliary muscle.
Details
- Status
- Prescription
- First Approved
- 2025-07-31
- Patent Cliff
- 2044
- Routes
- OPHTHALMIC
- Dosage Forms
- SOLUTION/DROPS
VIZZ Approval History
What VIZZ Treats
1 indicationsVIZZ is approved for 1 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Presbyopia
VIZZ Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to VIZZ
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VIZZ FDA Label Details
Indications & Usage
FDA Label (PDF)VIZZ is indicated for the treatment of Presbyopia.
VIZZ Patents & Exclusivity
Patents (6 active)
Exclusivity
Pro Intelligence Preview
Deep insights for VIZZ
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2044
- • 6 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 3 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.